Insider plans sale of 908 RVMD shares
Revolution Medicines shareholder Jeffrey Todd Cislini has filed a notice to sell common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Revolution Medicines shareholder Jeffrey Todd Cislini has filed a notice to sell common stock. The filing covers a planned sale of 908 common shares through Morgan Stanley Smith Barney LLC on or around 01/21/2026 on the NASDAQ market. These shares were acquired as restricted stock units from the issuer on 12/15/2025, and the block has an aggregate market value of $105,527.76.
The notice states that Revolution Medicines had 193,319,805 common shares outstanding at the time referenced. Over the prior three months, Cislini sold 2,688 common shares on 12/16/2025 for $206,483.83 and 13,388 common shares on 11/18/2025 for $939,008.57, with the larger transaction noted as Rule 10b5-1 sales. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What representation does the seller make in this RVMD Form 144 notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.